VX-770

Base Information Edit

Chemical Name:VX-770
CAS No.:873054-44-5
Molecular Formula:C24H28N2O3
Molecular Weight:392.498
Hs Code.:29333990
Mol file:873054-44-5.mol

Synonyms:Kalydeco;N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide;Ivacaftor;

Suppliers and Price of VX-770

Supply Marketing:Edit

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Usbiological
Ivacaftor
1mg
$ 638.00

TRC
Ivacaftor
1g
$ 365.00

TRC
Ivacaftor
100mg
$ 50.00

Sigma-Aldrich
CFTR Potentiator, VX-770 - CAS 873054-44-5 - Calbiochem
10 mg
$ 248.00

Sigma-Aldrich
CFTR Potentiator, VX-770 - CAS 873054-44-5 - Calbiochem
5305410001
$ 239.00

Medical Isotopes, Inc.
Ivacaftor
100 mg
$ 190.00

Matrix Scientific
N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide 95%
500mg
$ 491.00

Matrix Scientific
N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide 95%
1g
$ 733.00

DC Chemicals
Ivacaftor(VX-770) >99%
100 mg
$ 200.00

Crysdot
Ivacaftor 98+%
50mg
$ 795.00

Total 125 raw suppliers

Chemical Property of VX-770 Edit

Chemical Property:

Vapor Pressure:1E-12mmHg at 25°C
Refractive Index:1.605
Boiling Point:550.4 °C at 760 mmHg
PKA:11.08±0.23(Predicted)
Flash Point:286.7 °C
PSA：85.68000
Density:1.187 g/cm³
LogP:5.46500
Storage Temp.:Refrigerator
Solubility.:DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)

Purity/Quality:

99%, ^*data from raw suppliers

Ivacaftor ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Description In January 2012, the US FDA approved ivacaftor for the treatment of cystic fibrosis (CF) in patients who have the G551D mutation of the CF transmembrane regulator (CFTR) and are at least 6 years old. Ivacaftor (also known as VX-770) is a CFTR potentiator that increases the open probability of CFTR, thus increasing chloride secretion particularly in the 5% of CF patients with the G551D/F508 gating/ processing mutation. Ivacaftor was discovered by medicinal chemistry optimization of a lead scaffold identified through high-throughput screening of a 228,000 compound collection. In cultured bronchial epithelial cells from a CF patient with F508del, ivacaftor increased chloride secretion (EC50=81 nM). Preparation of ivacaftor is accomplished via a multistep synthesis oftwointermediates, 4-oxo-1,4-dihydroquinoline-3-carboxylic acid and 5-amino-di-tert-butylphenyl methyl carbonate, which are coupled using propane phosphonic acid anhydride (T3P) to afford the amide; deprotection of the phenol then provides ivacaftor.
Uses Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively Ivacaftor is used in the treatment of cystic fibrosis.
Clinical Use Vertex’s ivacaftor was granted breakthrough therapy designation by the FDA in January 2012 for cystic fibrosis (CF) patients who bear the G551D mutation in the Cycstic Fibrosis Transmembrane Regulator (CFTR) gene. This CFTR mutation occurs in roughly 4% of the 30,000 people living with CF in the United States. While the compound has been identified as a potentiator in cell-based assays, its mechanism of action is as yet unknown.

Technology Process of VX-770

There total 58 articles about VX-770 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 88.0%